We are live on ! Find out more
NFGH

Nan Fung Group Holdings Portfolio holdings

AUM $121M
1-Year Est. Return 56.89%
This Fund
S&P 500
This Quarter Est. Return
-2.85%
1 Year Est. Return
+56.89%
3 Year Est. Return
+244.35%
5 Year Est. Return
+210.19%
10 Year Est. Return
–
AUM
$338M
AUM Growth
+$25.6M
Cap. Flow
+$47.9M
Cap. Flow %
14.16%
Top 10 Hldgs %
83.48%
Holding
57
New
29
Increased
2
Reduced
–
Closed
2

Top Buys

Rank Stock Value
1
EXAI
Exscientia Plc American Depositary Shares
EXAI
+$16.2M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$7.59M
3
PACB icon
Pacific Biosciences
PACB
+$4.15M
4
ONC
BeOne Medicines Ltd
ONC
+$3.78M
5
INCY icon
Incyte
INCY
+$2.33M

Top Sells

Rank Stock Value
1
FLNT
Fluent
FLNT
+$442K
2
AKRO
Akero Therapeutics
AKRO
+$78K

Sector Composition

Rank Sector Weight
1 Healthcare 69.71%
2 Financials 28.31%
3 Communication Services 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KOD icon
26
Kodiak Sciences
KOD
$2.84B
$1.14M 0.34%
+13,440
New +$1.37M
KALV
27
DELISTED
KalVista Pharmaceuticals
KALV
$1.04M 0.31%
78,720
– –
ALXO icon
28
ALX Oncology
ALXO
$290M
$902K 0.27%
41,950
– –
ACAD icon
29
Acadia Pharmaceuticals
ACAD
$5.03B
$818K 0.24%
+35,035
New +$705K
BLUE
30
DELISTED
bluebird bio
BLUE
$783K 0.23%
+3,918
New +$925K
BMRN icon
31
BioMarin Pharmaceuticals
BMRN
$12.4B
$659K 0.2%
+7,460
New +$616K
STSA
32
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$643K 0.19%
142,900
– –
DBVT
33
DBV Technologies
DBVT
$847M
$594K 0.18%
37,095
– –
RUBY
34
DELISTED
Rubius Therapeutics, Inc
RUBY
$550K 0.16%
56,768
– –
DICE
35
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$499K 0.15%
+19,700
New +$577K
LEGN icon
36
Legend Biotech
LEGN
$4.01B
$435K 0.13%
+9,340
New +$474K
SRZN icon
37
Surrozen
SRZN
$301M
$419K 0.12%
+4,338
New +$492K
ARGX icon
38
argenx
ARGX
$54.1B
$396K 0.12%
+1,130
New +$344K
KYMR icon
39
Kymera Therapeutics
KYMR
$8.94B
$315K 0.09%
+4,960
New +$289K
TNGX icon
40
Tango Therapeutics
TNGX
$4.41B
$279K 0.08%
+25,500
New +$307K
MRTX
41
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$266K 0.08%
+1,810
New +$281K
PRLD icon
42
Prelude Therapeutics
PRLD
$390M
$253K 0.07%
+20,350
New +$331K
CNTA
43
DELISTED
Centessa Pharmaceuticals
CNTA
$250K 0.07%
+22,200
New +$299K
TCRX icon
44
TScan Therapeutics
TCRX
$52M
$219K 0.06%
+48,600
New +$351K
RETA
45
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$218K 0.06%
8,265
– –
BCRX icon
46
BioCryst Pharmaceuticals
BCRX
$2.4B
$215K 0.06%
+15,545
New +$206K
AMYT
47
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$207K 0.06%
+19,150
New +$207K
DAWN
48
DELISTED
Day One Biopharmaceuticals
DAWN
$193K 0.06%
+11,445
New +$235K
ABCL icon
49
AbCellera Biologics
ABCL
$2.12B
$188K 0.06%
+13,180
New +$200K
ATYR
50
aTyr Pharma
ATYR
$50.1M
$176K 0.05%
+23,500
New +$196K
1
2
3

Similar funds

MAM
Mirabaud Asset Management London, United Kingdom $121M AUM 20.69% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
CCM
Candelo Capital Management New York $121M AUM 113.39% 1-Year Est. Return
CCM
CFO Capital Management Fairfield, Connecticut $121M AUM
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
RIP
Reliant Investment Partners Pinehurst, North Carolina $121M AUM 34.77% 1-Year Est. Return
CF
Conquis Financial Milbrae, California $121M AUM 16.22% 1-Year Est. Return
MW
Merited Wealth North Bay Village, Florida $121M AUM

Nan Fung Group Holdings's Q4 2021 Portfolio in Review

As of Q4 2021, Nan Fung Group Holdings held 57 positions worth $338M, up 8.2% from $312M the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Nan Fung Group Holdings deployed $47.9M of net new capital in Q4 2021, opening 29 new positions and adding to 2 existing holdings. Its largest new stake was Exscientia Plc American Depositary Shares: 770,200 shares worth $15.2M.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 67% a quarter earlier, followed by Financials and Communication Services.

On the sell side, the most notable exit was Fluent, an estimated $442K sold.

  • Nan Fung Group Holdings's largest Q4 2021 buy was Exscientia Plc American Depositary Shares: 770,200 shares worth $15.2M.
  • Nan Fung Group Holdings added most to Vir Biotechnology in Q4 2021, an estimated $1.97M increase.
  • Nan Fung Group Holdings fully exited Fluent in Q4 2021, selling an estimated $442K.
  • Nan Fung Group Holdings's ten largest holdings make up 83% of its $338M portfolio in Q4 2021.
  • Nan Fung Group Holdings opened 29 new positions and closed 2 in Q4 2021.
  • Nan Fung Group Holdings's portfolio value rose 8.2% quarter-over-quarter to $338M.

Based on Nan Fung Group Holdings's 13F filing for Q4 2021, filed 14 Feb 2022.